Global FAP Inhibitors Market Forecast 2025: Pipeline & Revenue Insights
According to a newly published market research report by 24LifeSciences, global Fibroblast Activation Protein Inhibitors market was valued at USD 73.5 million in 2024 and is projected to reach USD 248.9 million by 2032, growing at a compound annual growth rate (CAGR) of 16.1% during the forecast period 2025–2032.
Fibroblast Activation Protein (FAP) inhibitors are a novel class of therapeutics and diagnostics that target a cell-surface serine protease highly expressed in the cancer-associated fibroblasts (CAFs) of over 90% of epithelial carcinomas. These inhibitors are designed to impede tumor growth because FAP plays a crucial role in tumor progression, immunosuppression, and metastasis by remodeling the extracellular matrix. The primary product types include Ga-labeled and F-labeled inhibitors, which are used for both tumor diagnosis, via PET imaging, and therapeutic applications.
Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/11097/fibroblast-activation-protein-inhibitors-market-market
